Related Experiment Video
Updated: May 16, 2025

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Breaking New Ground With Endoxifen: Augmentation Strategies in OCD Management-A Case Series
Rishabh Singh1, Markanday Sharma2, Samiksha Sahu3
1Department of Psychiatry, Command Hospital (Eastern Command), Kolkata, West Bengal, India.
Abstract:
Obsessive-compulsive (OC) disorder (OCD) is a common and potentially disabling illness with a waxing and waning course. OCD significantly disrupts the quality of life. Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmacological treatments for OCD and benefit up to half of the patients. Augmentation with low-dose antipsychotics is an evidence-based second-line strategy. Psychotherapy, including cognitive behavior therapy (CBT), is used both as first and second-line treatment. A significant portion of patients, however, do not respond to conventional treatments. We present a case series on the use of Endoxifen as an augmenting agent in patients with OCD and multiple psychiatric comorbidities who did not respond well to conventional pharmacotherapy.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Operant Conditioning Intervention
In operant conditioning, behaviors that are...
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

